© 2021 MJH Life Sciences and Cure Today. All rights reserved.
© 2021 MJH Life Sciences™ and Cure Today. All rights reserved.
March 23, 2021
The phase 3 ARIEL4 trial evaluated Rubraca (rucaparib) versus chemotherapy in patients with ovarian cancer and a BRCA mutation who did not respond to two or more lines of chemotherapy.
July 23, 2020
June 23, 2020
Immunotherapy with Keytruda shows promise in advanced uncommon cancers in which new treatment options are needed.
May 29, 2020
“These long-awaited trial results will change clinical practice,” lead study author Dr. Thierry André, of the Sorbonne Université and Hôpital Saint Antoine in Paris, said in an ASCO-issued press release.
Unconventional Candidate For a Lung Cancer Hero
Perhaps a Pearl: An Experience That Led to Meeting Another Breast Cancer Survivor
An Oncology Nurse Wears Many Hats
Inaccurate Information on Cancer Diagnosis and Treatment Common on Social Media Sites